Lanreotide for the treatment of patients with disseminated high-grade neuroendocrine tumors: the experience of application in case of unsatisfactory tolerability of octreotide


Cite item

Full Text

Abstract

Somatostatin analogs plays a key role in the treatment of disseminated well-differentiated functioning and nonfunctioning neuroendocrine tumors (NET). Its ingibit hormonal activity of NET by binding to somatostatin receptors, have antiproliferative effect, increase the median time to progression. Approximately 10% of patients have significant side-effects when used octreotide. Octreotide and lanreotide differ in structure. Intolerance to one drug, it may be assigned to another.

About the authors

G S Emelyanova

A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation

Email: docgalina@mail.ru
канд. мед. наук, ассистент каф. онкологии ФДПО ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

A E Kuzminov

N.N.Blokhin Russian Cancer of the Ministry of Health of the Russian Federation

канд. мед. наук, науч. сотр. отд-ния химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

N F Orel

N.N.Blokhin Russian Cancer of the Ministry of Health of the Russian Federation; Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation

д-р мед. наук, вед. науч. сотр. отд-ния химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина, проф каф. онкологии ГБОУ ДПО РМАПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

A S Odintsova

N.N.Blokhin Russian Cancer of the Ministry of Health of the Russian Federation

канд. мед. наук, врач отд-ния химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

A A Markovich

N.N.Blokhin Russian Cancer of the Ministry of Health of the Russian Federation

канд. мед. наук, ст. науч. сотр. отд-ния амбулаторных методов диагностики и лечения ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

A A Kuznetsova

N.N.Blokhin Russian Cancer of the Ministry of Health of the Russian Federation

аспирант отд-ния химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

V A Gorbunova

N.N.Blokhin Russian Cancer of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., зав. отд-нием химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

References

  1. Patel Y.C, Murthy K.K, Escher E.E et al. Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins. Metabolism 1990; 39 (9 Suppl. 2): 63-9.
  2. Lahlou H, Guillermet J, Hortala M et al. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci 2004; 1014: 121-31.
  3. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005; 89: 151-60.
  4. Bajetta E, Carnagi С, Ferrari L et al. The role of somatostatin analogues in the treatment of gastroenteropancreatic endocrine tumors. Digest 1996; 57 (Suppl. 1): 72-7.
  5. Battershill P.E, Clissold S.P. Octreotide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989; 38: 658-702.
  6. Kvols L.K, Moertel C.G, O'Connell M.J et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long - acting somatostatin analogue. N Engl J Med 1986; 315 (11): 663-6.
  7. Lightman S. Somatuline autogel: An eхtended release lanreotide formularion. Hosp 2002; 315: 246-54.
  8. Oberg K, Kvols L.K, Caplin M et al. Consensus report on the se of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15 (6): 966-73.
  9. Ricci S, Antonuzzo A, Galli L et al. Long - acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000; 23 (4): 412-5.
  10. Kaltsas G.A, Stefanidou Z, Papadogias D, Grossman A.B. Treatmentof advanced neuroendocrine tumors with the radiolabelled somatostatin analogue octreotide. Hormones (Athens). 2002; 1 (3): 149-56.
  11. Grozinssky-Glasberg S, Shimov I, Korbonits M, Grossvan A.B. Somatostatin analogues in control of the control of neuroendocrine tumors: efficacy and mechanisms. Endocr Relat Cancer 2008; 15 (3): 701-20.
  12. Rinke A, Muller H, Schade-Brittinger C et al. R Placebo - controlled, double - blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-63.
  13. Ruszniewski P, Ish-Shalom S, Wymenga M et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged - release formulation of lanreotide. Neuroendocrinology 2004; 80 (4): 244-51.
  14. Caplin M.E, Pavel M, Ćwikła J.B et al. N Lanreotide in metastatic enteropancreatic neuroendocrine tumors. CLARINET Investigators. Engl J Med 2014; 371 (3): 224-33.
  15. th Annual Conferens for the Diagnosis and Treatment of Neuroendocrine Tumor Disease 11-13 March 2015, Barcelona, Spain, ENETS abstractbook.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies